Low-Dose Naltrexone Medication for Autoimmune Disease Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases like multiple sclerosis (MS), fibromyalgia, depression, and autoimmune diseases are only marginally effective in reducing progression and reversing symptoms, often lead to immune suppression, increasing the risk of infections and cancer, and stimulate antibody production, which negates further benefits.
Innovation Solution
A medication combination of low-dose naltrexone, vitamins B12 and B6, and coenzyme Q, optionally with ancillary medications like anticonvulsants, muscle relaxants, and anxiolytics, administered orally to reduce disease progression and alleviate symptoms such as fatigue, muscle spasms, and nerve pain without immune suppression or antibody formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immune suppression therapy is used to treat autoimmune diseases, then the immune response is suppressed, but the patient becomes susceptible to infections and cancer
Solution Approach 1:
Instead of suppressing the immune system as in traditional therapy, the patent uses naltrexone to modulate and regulate immune function, reversing the approach from suppression to balanced regulation. This allows treatment of autoimmune diseases while maintaining immune defense capabilities against infections and cancer
Solution Approach 2:
The patent changes the dosing parameter of naltrexone to low doses (1-10 mg daily), which produces different effects compared to high doses. At low doses, naltrexone modulates immune function beneficially without causing the harmful immune suppression and increased infection risk associated with traditional high-dose or immunosuppressive therapies
2Reliability
If traditional treatments are used to reduce disease progression, then some symptom reduction is achieved, but the treatments are only marginally effective and do little to reverse symptoms
Solution Approach 1:
The patent combines naltrexone with vitamin B12 and coenzyme Q10 to create a composite treatment formulation. This combination produces synergistic effects that enhance both disease progression reduction and symptom reversal capabilities, overcoming the marginal effectiveness of single-agent traditional treatments
Solution Approach 2:
The patent introduces vitamin B12 and coenzyme Q10 as intermediary substances that work alongside naltrexone to enhance therapeutic effects. These intermediaries support nerve function, energy metabolism, and overall cellular health, thereby improving both disease progression control and symptom reversal
3Reliability
If traditional immuno-suppressors are used, then immune response is inhibited, but antibodies are promoted and formed which negate further benefit
Solution Approach 1:
Instead of using immuno-suppressors that inadvertently promote antibody formation, the patent inverts the approach by using low-dose naltrexone to regulate immune function in a way that reduces autoimmune activity without triggering harmful antibody responses. This maintains immune system balance rather than creating new problems
Data Source
AI summary
A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.